Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Select Drug Profiles
FDA Approvals
,
In the News
,
Select Drug Profiles
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
March 08, 2019 - FDA Approvals, News & Updates
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
FDA Approves Split-Dosing Regimen for Daratumumab in Patients with Multiple Myeloma
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
February 1, 2019 - FDA Approvals, News & Updates
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
Government Shutdown Impacts FDA Drug Approvals
Read More
FDA Approvals
,
Select Drug Profiles
A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Gillian Woollett, MA, DPhil
,
Bruce S. Pyenson, FSA, MAAA
Read More
Select Drug Profiles
,
Payers' Guide
Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea
Loretta Fala
Read More
Select Drug Profiles
,
Payers' Guide
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh
Read More
Select Drug Profiles
,
Payers' Guide
Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
7
8
9
10
11
12
13
Page 10 of 20
Results 91 - 100 of 200